Post by marriott on Apr 7, 2015 22:33:06 GMT
Market Has Not Yet Noticed Potential in Geron (GERN); Have You? - Tale of the Tape
Zacks
By Zacks Equity Research 9 hours ago
It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach.
So, instead of repenting, spotting the off-the-radar potential winners and immediately investing in them could be a smart decision.
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Geron Corporation (GERN). This Medical-Biomedical/Generic stock has actually seen estimates rise over the past month for the current fiscal year by about 93.0%. But that is not yet reflected in its price, as the stock lost 1.3% over the same time frame.
You should not be concerned about the price remaining muted going forward. This year’s expected earnings growth over the prior year is 95.7%, which should ultimately translate into price appreciation.
And if this isn’t enough, GERN currently carries a Zacks Rank #2 (Buy) which further underscores the potential for its outperformance (See the performance of Zacks' portfolios and strategies here: About Zacks Performance).